2017, Number S1
<< Back Next >>
Rev Cubana Pediatr 2017; 89 (S1)
Nasopharyngeal colonization of pneumococci in the Cuban infant population, prevalence study-based evidence
Toledo-Romaní ME, Chávez AD, Casanova GMF, Toraño PG, Linares-Pérez N
Language: Spanish
References: 34
Page: 86-97
PDF size: 155.45 Kb.
ABSTRACT
Introduction: a new Cuban pneumococcal vaccine undergoes the evaluation phase in
Cuba and its introduction represents a health care system priority. Population-based
data on the burden of nasopharyngeal colonization are scarce.
Objective: to estimate the prevalence of colonization and to identify the circulating
serotypes in children aged 2 to 18 months and 1 to 5 years from Cienfuegos
municipality in the period of 2013 through 2015 before the introduction of
pneumococcal vaccination, in order to measure the impact of the new vaccine and to
monitor the serotype replacement phenomenon.
Methods: two cross-sectional surveys comprising children aged 2 to 18 months
(phase I) and 1 to 5 years-old, who go to daycare centers (phase II), were made. The
inclusion criteria were evaluated and the parents gave their informed consent. The
nasopharyngeal exudate samples were taken according to the set protocols. The
colonization prevalence was estimated as well as the most common serotypes in both
age strata were identified. The data analysis included the frequency distribution and
the ratio comparison.
Results: the global prevalence of colonization in 984 children aged 2 to 18 months in
the first stage was 21.6 %. The most common serotypes were 6A (23.1 %), 23F
(10.8 %), 6B (10.3 %), 19F (8.5 %) and 14 (3.3 %). In the second phase of the
study, 1 135 one-five years old children participated. The global colonization
prevalence significantly increase (31.01 %) in children going to day care centers. In
both study groups, the vaccinal serotypes were predominant and the circulation
pattern was similar.
Conclusions: the findings suggest that the burden of pneumococcal disease and the
nasopharyngeal colonization in children under five years could be significantly
influenced by the introduction of the new Cuban pneumococcal vaccine.
REFERENCES
Publication WHO. Pneumococcal vaccines WHO position paper-2012- recommendations. Vaccine. 2012;30(32):4717-8.
Bogaert D, de Groot R, Hermans P. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. The Lancet Infectious Diseases. 2004;4(3):144-54.
Croucher NJ, Kagedan L, Thompson CM, Parkhill J, Bentley SD, Finkelstein JA, et al. Selective and genetic constraints on pneumococcal serotype switching. PLoS Genet. 2015;11(3):e1005095.
Calix JJ, Nahm MH. A new pneumococcal serotype, 11E, has a variably inactivated wcjE gene. Journal of Infectious Diseases. 2010;202(1):29-38.
Ziane H, Manageiro V, Ferreira E, Moura IB, Bektache S, Tazir M, et al. Serotypes and antibiotic susceptibility of Streptococcus pneumoniae isolates from invasive pneumococcal disease and asymptomatic carriage in a pre-vaccination period, in Algeria. Front Microbiol. 2016;7:803-10.
Calix JJ, Porambo RJ, Brady AM, Larson TR, Yother J, Abeygunwardana C, et al. Biochemical, genetic, and serological characterization of two capsule subtypes among Streptococcus pneumoniae serotype 20 strains discovery of a new pneumococcal serotype. Journal of Biological Chemistry. 2012;287(33):27885-94.
Fitzwater SP, Chandran A, Santosham M, Johnson HL. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. The Pediatric Infectious Disease Journal. 2012;31(5):501-8
Afonso ET, Minamisava R, Bierrenbach AL, Escalante JJ, Alencar AP, Domingues CM, et al. Effect of 10-valent pneumococcal vaccine on pneumonia among children, Brazil. Emerging Infectious Diseases. 2013;19(4):589-97.
Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. The Lancet. 2013;381(9862):214-22.
De Wals P, Lefebvre B, Defay F, Deceuninck G, Boulianne N. Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiD-CV in the province of Quebec, Canada. Vaccine. 2012;30(45):6416-20.
Gonçalves FP, Abreu TC, Alves M, dos Anjos R, de Souza L, Gomes H, et al. Nasopharyngeal carriage, serotype distribution and antimicrobial resistance of Streptococcus pneumoniae among children from Brazil before the introduction of the 10-valent conjugate vaccine. BMC Infectious Diseases. 2013;13:318.
González N, Paredes B, Pérez S, Mirabal M, Rivero I, González C, et al. Safety and immunogenicity of Cuban antipneumococcal conjugate vaccine PCV7-TT in healthy adults. MEDICC Review. 2015;17(4):32-7.
Dotres CP, Puga R, Ricardo Y, Brono CR, Paredes B, Echemendía V, et al. Safety and preliminary immunogenicity of Cuban pneumococcal conjugate vaccine candidate in healthy children: A randomized phase I clinical trial. Vaccine. 2014;32(41):5266-70.
Mokaddas E, Albert MJ. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: An overview from Kuwait. Vaccine. 2012;30(6):37-40.
Farooqui H, Jit M, Heymann DL, Zodpey S. Burden of Severe Pneumonia, Pneumococcal Pneumonia and Pneumonia Deaths in Indian States: Modelling Based Estimates. PLoS ONE. 2015;10(6):e0129191.
World Health Organization & Centers for Disease Control and Prevention. Laboratory methods for the diagnosis of meningitis caused by Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae [homepage en Internet]; WHO manual, 2011 [citado 12 de Julio de 2016]. Disponible en: http://apps.who.int/iris/handle/10665/70765
Team RC. (2014). R: A language and environment for statistical computing. R Foundation for Statistical Computing [homepage en Internet]; Vienna, Austria. 2013 [citado 9 de Mayo de 2016]. Disponible en: http://cran.fiocruz.br/web/packages/dplR/vignettes/timeseries-dplR.pdf
Dobay O, Amyes SG, Nagy K. The effect of the 7-valent conjugate vaccine (PCV7) on the incidence of pneumococcal infections world-wide. Reviews in Medical Microbiology. 2008;19(3):79-85.
Complete P. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2010;59:258-61.
Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L. Prevention of pneumococcal diseases in the post-seven valent vaccine era: A European perspective. BMC Infectious Diseases. 2012;12:207-11.
Dagan R. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic‐resistant Streptococcus pneumoniae. Clinical Microbiology and Infection. 2009;15(3):16-20.
Soewignjo S, Gessner BD, Sutanto A, Steinhoff M, Prijanto M, Nelson C, et al. Streptococcus pneumoniae nasopharyngeal carriage prevalence, serotype distribution, and resistance patterns among children on Lombok Island, Indonesia. Clinical Infectious Diseases. 2001;32(7):1039-43.
Adegbola RA, De Antonio R, Hill PC, Roca A, Usuf E. Carriage of Streptococcus pneumoniae and Other Respiratory Bacterial Pathogens in Low and Lower-Middle Income Countries: A Systematic Review and Meta-Analysis. PLoS ONE. 2014;9(8):e103293.
Hammitt L, Bruden L, Butler JC, Baggett HC, Hurlburt DA, Reasonover A, et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. Journal of Infectious Diseases. 2006;193(11):1487-94.
Cutts F, Zaman S, Enwere Gy, Jaffar S, Levine O, Okoko J, et al. Efficacy of ninevalent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. The Lancet. 2005;365(9465):1139-46.
Ghaffar F, Barton T, Lozano J, Muniz LS, Hicks P, Gan V, et al. Effect of the 7- valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clinical Infectious Diseases. 2004;39(7):930-8.
Isaacman DJ, Mc Intosh ED, Reinert R. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.International Journal of Infectious Diseases. 2010;14(3):197-209.
Hill PC, Onyeama CO, Ikumapayi UN, Secka O, Ameyaw S, Simmonds N, et al. Bacteraemia in patients admitted to an urban hospital in West Africa. BMC Infectious Diseases. 2007;7(1):2.
García-Vera C. Estado de portador de neumococo en niños y su relación con la enfermedad invasiva. Qué ha cambiado tras la introducción de vacunas conjugadas? Rev Pediatr Aten Primaria. 2010;XII(47):457-82.
Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger R, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Medicine. 2010;7(10):1251.
Brink AJ, Cotton MF, Feldman C, Geffen L, Hendson W, Hockman MH, et al; Working Group of the Infectious Diseases Society of South Africa. Guideline for the management of upper respiratory tract infections. S Afr Med J. 2004 Jun;94(6 Pt 2):475-83.
Brandileone MCC, Zanella RC, Almeida SCG, Brandao AP, Riveiro AF, Carvalhanas TRMP, et al. Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in São Paulo, Brazil. Vaccine [serie en Internet]. 2016 [citado 12 de Octubre de 2016];34(6). Disponible en:http://www.sciencedirect.com/science/article/pii/S0264410X16308404
Toraño G, Pérez L, Abreus M, Rodríguez M, Dickinson F, Valcarcel M, et al. Serotipos y resistencia antimicrobiana de aislamientos meníngeos de Streptococcus pneumoniae, Cuba, 2007-2012. VacciMonitor. 2014;23(3):117-23.
Agudelo CI, Castañeda E, Corso A, Regueira M, Brandileone M, Brandão AP, et al. Resistencia a antibióticos no betalactámicos de aislamientos invasores de Streptococcus pneumoniae en niños latinoamericanos. SIREVA II, 2000-2005. Rev Panam Salud Pública. 2009;25(4):305-13.